Novozymes A/S
DUS:NZM2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novozymes A/S
DUS:NZM2
|
DK |
|
R
|
Rio Tinto PLC
NYSE:RIO
|
UK |
|
C
|
Credit Agricole SA
XMUN:XCA
|
FR |
|
Proteome Sciences PLC
LSE:PRM
|
UK |
|
Levi Strauss & Co
NYSE:LEVI
|
US |
|
O
|
Origin Bancorp Inc
NYSE:OBK
|
US |
|
MGIC Investment Corp
NYSE:MTG
|
US |
|
US Gold Corp
NASDAQ:USAU
|
US |
|
B
|
Banco Santander Brasil SA
BOVESPA:SANB3
|
BR |
|
S
|
Sberbank Rossii PAO
LSE:SBER
|
RU |
|
Itau Unibanco Holding SA
NYSE:ITUB
|
BR |
|
B
|
Best Buy Co Inc
BMV:BBY
|
US |
|
Buckle Inc
NYSE:BKE
|
US |
|
C
|
CVS Health Corp
DUS:CVS
|
US |
|
P
|
Persol Holdings Co Ltd
TSE:2181
|
JP |
Wall St Price Targets
NZM2 Price Targets Summary
Novozymes A/S
According to Wall Street analysts, the average 1-year price target for NZM2 is 63.37 EUR with a low forecast of 51.3 EUR and a high forecast of 77.47 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NZM2's stock price target?
Price Target
63.37
EUR
According to Wall Street analysts, the average 1-year price target for NZM2 is 63.37 EUR with a low forecast of 51.3 EUR and a high forecast of 77.47 EUR.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.
